Prostate Cancer Is No Longer One Disease! How Do Subtypes Change Treatment?

The Histopathological “Umbrella”: Acinar, Ductal/Intraductal and Neuroendocrine

Prostate cancer has several basic microscopic appearances (subtypes). The most common is acinar adenocarcinoma. Sometimes, a ductal or intraductal component accompanies it, potentially producing more aggressive behavior. After prolonged hormonal suppression, a rarer neuroendocrine (small cell) type may develop, with very different biology and treatment.

1) Conventional Acinar Adenocarcinoma

The most common type. Major determinants of its course are pathological grade (Gleason/ISUP), tumor extent, surgical margins and lymph node status.

For treatment selection, molecular tests (HRR, MSI/MMR, PTEN, SPOP, AR-V7) provide important clues. At intermediate–high-risk diagnosis, NGS (a genetic panel) and selected immunohistochemistry tests (e.g., PTEN) support decisions.

2) Ductal and Intraductal Components

• Ductal adenocarcinoma: Generally tends toward high-grade and more aggressive disease, with increased recurrence and metastasis risk.
• Intraductal carcinoma (IDC-P): Frequently associated with high tumor burden and genetic instability , suggesting a potentially worse prognosis.
• Management: These findings generally favor intensified treatment and early molecular testing .

3) Neuroendocrine (NE) Spectrum and Small Cell Variant

Usually developing under prolonged androgen (hormone) suppression , this type results from cellular reprogramming (lineage plasticity). Loss of protective genes such as TP53/RB1 often accompanies it.

• Clinical clues: Rapid progression, involvement of liver/lung and other visceral organs, elevated LDH or neuroendocrine markers.
• Treatment: Because it is independent of the androgen pathway, platinum-etoposide or platinum-taxane regimens are often preferred.

📊 Quick Comparison

🧬 Transcriptomic Classification: Basal–Luminal Distinctions with PAM50 and PCS

As in breast cancer, gene expression in prostate tumors can identify Luminal A, Luminal B and Basal , among other intrinsic subtypes . The prostate-specific PCS classification adds detail.

1) PAM50: Luminal and Basal

• Luminal A: Relatively indolent; more dependent on hormonal pathways.
• Luminal B: More aggressive; sensitive to hormonal pathways but may require earlier intensive treatment.
• Basal: Weak hormone dependence; may respond relatively better to chemotherapy .

2) Matching with PCS (Prostate Cancer Subtypes)

• PCS1 ≈ Luminal B: The most aggressive group, with shorter survival.
• PCS2 ≈ Luminal A: A better course, dependent on hormonal pathways.
• PCS3 ≈ Basal: AR-negative phenotype; signals favoring chemotherapy.

3) Clinical Implications

• Luminal (particularly Luminal B / PCS1): Response to AR-pathway drugs is expected; early intensification may be considered.
• Basal (PCS3): ARSI response may be limited; evidence favors taxane chemotherapy.

These subtypes are not yet fully incorporated into routine reports but are increasingly used in trials and decision-support systems.

Key message: Luminal B/PCS1 is a higher-risk group; Basal/PCS3 may favor chemotherapy.

Genomic Subtypes: Indicators That Change Treatment

HRR (such as BRCA), MSI-H/dMMR, PTEN loss, SPOP and AR-V7 and similar genetic findings are powerful tools for determining prognosis and which treatment may be most beneficial.

1) DNA Repair (HRR) Mutations

• Frequency: Collectively 20–30% in advanced disease; BRCA2 alone ~10%.
• Treatment: PARP inhibitors (often with ARSI) may provide substantial benefit.

2) MSI-H/dMMR & High TMB

• Frequency: Approximately 2–5%.
• Treatment: PD-1 inhibitors may produce strong, durable responses .
• Tip: The NGS report must assess MSI/MMR .

3) PTEN Loss / PI3K–AKT Activation

• Frequency: 40–50% in advanced disease.
• Treatment: In selected patients, ipatasertib + abiraterone and other AKT-targeted combinations may help.

4) SPOP Mutation

This alteration affects AR signaling and may be associated with better responses to hormonal pathway drugs (abiraterone, enzalutamide).

5) AR-V7 Splice Variant

• How Is It Tested? Usually through liquid biopsy / CTC testing.
• What Does It Indicate? The response to ARSI (abiraterone/enzalutamide) may be weak ; taxane chemotherapy may be more appropriate.

These genetic indicators are no longer confined to research; in everyday practice , they directly change treatment sequencing.

🔄 Lineage Plasticity and Neuroendocrine Transformation

Under prolonged hormonal suppression, some tumor cells change direction (plasticity), becoming hormone-independent. This may produce NEPC and double-negative (AR−/NE−) subtypes, usually with a more challenging clinical course.

What Triggers Plasticity?

TP53, RB1, PTEN Loss and other genetic changes, together with EZH2/SOX2/N-MYC and similar epigenetic factors. Targeting this axis may enable treatments that prevent plasticity in the future.

🧭 Clinical Summary and Testing Algorithm

These steps help translate subtype information into practice:

🔍 Priority Tests

• HRR panel (BRCA1/2, ATM, PALB2, CHEK2, CDK12): Key to PARP decisions.
• MSI/MMR: In 2–5% of patients, immunotherapy may become an option.
• PTEN (IHC/NGS): Identifies candidates for AKT-targeted combinations.
• SPOP: May indicate ARSI response.
• AR-V7 (CTC): Predicts ARSI resistance, favoring taxanes .

📊 Subtype–Treatment Matching (Brief Guide)

🩺 Practical Roadmap

1. New metastatic patient: Assess HRR, MSI/MMR and PTEN with NGS + IHC.
2. mCRPC stage: If planning ARSI, consider AR-V7 testing.
3. Aggressive phenotype: (high LDH, visceral metastases, brief PSA response) → possible NEPC/Double-Neg.; repeat biopsy + platinum regimens.
4. Transcriptomic subtype: (PAM50/PCS) may influence sequencing according to center experience/trials.

References

1. Aggarwal R, et al. JAMA Oncology, 2021. Prognosis Associated With Luminal and Basal Subtypes of Metastatic Castration-Resistant Prostate Cancer.
   A large study demonstrating associations between luminal–basal classification and survival and treatment (particularly AR-pathway agents) in mCRPC.
2. Agarwal N, et al. The Lancet, 2023. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2).
   Reports significantly prolonged rPFS with talazoparib + enzalutamide; supports PARP + ARSI strategies in the context of HRR alterations.
3. Lenis AT, et al. Clinical Cancer Research, 2024. Microsatellite Instability, Tumor Mutational Burden, and Clinical Outcomes in Prostate Cancer.
   Quantifies MSI-H/dMMR and high TMB prevalence, their association with outcomes and their clinical relevance to immunotherapy in prostate cancer.